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The inflammatory myopathies constitute a heterogeneous group of acquired myopathies that have in common the presence of endomysial inflammation. Based on
steadily evolved clinical, histological and immunopathological features and some
autoantibody associations, these disorders can now be classified in five characteristic subsets: Dermatomyositis (DM) Polymyositis (PM), Necrotizing Autoimmune
Myositis (NAM), Anti-synthetase syndrome-overlap myositis (Anti-SS-OM), and
Inclusion-Body-Myositis (IBM). Each inflammatory myopathy subset has distinct
immunopathogenesis, prognosis and response to immunotherapies, necessitating
the need to correctly identify each subtype from the outset to avoid disease mimics and proceed to early therapy initiation. The review presents the main clinicopathologic characteristics of each subset highlighting the importance of combining expertise in clinical neurological examination with muscle morphology and
immunopathology to avoid erroneous diagnoses and therapeutic schemes. The
main autoimmune markers related to autoreactive T cells, B cells, autoantibodies
and cytokines are presented and the concomitant myodegenerative features seen
in IBM muscles are pointed out. Most importantly, unsettled issues related to a
role of autoantibodies and controversies with reference to possible triggering factors related to statins are clarified. The emerging effect SARS-CoV-2 as the cause
of hyperCKemia and potentially NAM is addressed and practical guidelines on
the best therapeutic approaches and concerns regarding immunotherapies during
COVID-19 pandemic are summarized.
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Introduction
Inflammatory myopathies (IM) are a heterogeneous group of acquired
myopathies that have in common the presence of inflammation in the
muscle. Based on distinct clinical, histological, immunopathological and
autoantibody features, they have evolved in five distinct subsets: Dermatomyositis (DM), Polymyositis (PM), Necrotizing Autoimmune Myositis
(NAM), Anti-synthetase syndrome-overlap myositis (Anti-SS-OM), and Inclusion-Body-Myositis (IBM) 1-6. Each subset has distinct clinical features,
pathogenesis, response to therapies and different prognosis requiring careful
clinicopathologic correlation with expertise in muscle histopathology for a
correct diagnosis and distinction from disease mimics. The article describes
the main clinicopathologic and immune features of all subtypes, highlights
289
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how best to avoid erroneous diagnoses, and provides practical guidelines on therapeutic approaches.
Patients with all IM forms experience slow, subacute
and rarely acute onset of difficulty performing tasks requiring the use of proximal muscles, such as climbing steps or
getting up from a chair; patients with IBM however, may
present first with weakness in the distal muscles of hands
and feet and difficulties with buttoning, typing or raising
toes and feet. Neck-extensor and pharyngeal muscles can
be affected in all subsets resulting in difficulty holding up
the head (head drop) and dysphagia. In advanced cases,
respiratory muscles can be affected. Myalgia and muscle
tenderness may also occur, most often in anti-SS-OM;
if myalgia is prominent, a co-existent fasciitis should be
considered. Extramuscular manifestations may occur in
all IM, but rarely in IBM, and include arthralgia, Raynaud’s phenomenon and pulmonary complications due
to interstitial lung disease as seen in anti-SS-OM 1-6 or
in amyopathic DM with anti-Melanoma Differentiation–
Associated protein-5 [MDA-5] antibodies 1,7.

Clinical characteristics
Dermatomyositis (DM)
DM, seen in both children and adults, presents with
characteristic skin manifestations accompanying or preceding muscle weakness. Periorbital heliotrope (blue-purple) rash with edema, erythematous rash on face, knees,
elbows, malleoli, neck, anterior chest (in V-sign), back
and shoulders (in shawl sign), and knuckles with a violaceous eruption (Gottron’s rash) that evolves into a scaling
discoloration, are typical skin lesions 1-8. Dilated capillary
loops at the base of the fingernails, irregular and thickened cuticles, and cracked palmar fingertips (“mechanic’s
hands”) are also characteristic 1-4. Subcutaneous calcifications, sometimes extruding to the surface, were common
in our practice 20-30 years ago especially in children, as
highlighted 8, but they are rarely seen today due to early initiation of effective immunotherapies. When DM is
clinically limited to the skin (amyopathic dermatomyositis), the patients seem to have normal strength, but their
muscle is always subclinically involved; based on our
experience with a number of such patients we have biopsied, their muscle shows the typical features of DM described below but to a lesser degree 9. In children, an early
symptom is “misery,” defined as an irritable child with
red-flush on face, fatigue and reluctance to socialize 1-4.
Dermatomyositis may overlap with systemic sclerosis
and mixed connective tissue disease and requires distinction from the anti-SS-OM subset. In adults with DM there
is a malignancy risk in up to 15% of patients, especially
in the first 3-5 years from the disease onset 1,8. Common
cancers are ovarian, breast, colon, melanoma, nasophar290

ynx (in Asians) and non-Hodgkin lymphoma, necessitating a thorough annual work-up the first 3 years 10.
Polymyositis (PM)
PM is a very rare entity. In our experience most patients referred for PM have another disease most often
IBM, NAM, or an inflammatory dystrophy 1-3. Polymyositis does exist but remains a diagnosis of exclusion. It is
best defined as a subacute proximal myopathy in adults
who do not have rash, family history of neuromuscular
disease, exposure to myotoxic drugs (d-penicillamine,
zidovudine), involvement of facial and extraocular muscles, endocrinopathy, or the clinical phenotype of IBM 1-3.
Necrotizing Autoimmune Myositis (NAM)
NAM, also referred by some as Immune-mediated necrotizing myopathty (IMNM), has now evolved as the most
common IM subtype 1. It starts either acutely reaching its
peak over days or weeks, or subacutely progressing steadily
causing severe weakness and very high creatine kinase (CK)
levels in the thousands 1. NAM may also occur after viral
infections and in association with cancer or immune check
point inhibitors as discussed later. Unfortunately, very often
NAM is erroneously attributed to statins or over-diagnosed
as a “statin-myopathy” in patients on chronic statin administration 11, even though there is no convincing evidence as
explained later. Acute rhabdomyolysis, like seen in NAM,
can very rarely coincide with statin initiation and may be
the causative factor in some cases of acute-onset NAM but
there is no convincing evidence that statins play a triggering
role in patients who develop a subacute NAM, while taking statins for years and their myopathy continues to worsen even after statin withdrawal 1,11,12. Most NAM patients
have antibodies against signal recognition particle (SRP) or
3hydroxy3-methylglutaryl-coenzyme A reductase (HMGCR) 1,11,14 as discussed later.
Anti-synthetase syndrome-Overlap Myositis (Anti-SS-OM)
Anti-SS-OM, often presents with systemic sclerosis-like lesions, mild-to-moderate proximal muscle
weakness, arthritis in the form of subluxation of the interphalangeal joints, “mechanic’s hands”, Raynaud phenomenon, and interstitial lung disease 1. The syndrome is
highlighted by the presence of anti-synthetase antibodies,
primarily anti-Jo-1, hence the naming of anti-Jo-1 syndrome, and distinct histology with necrotizing features in
the perimysium and perifascicular muscle fibers 1,11,16.
Inclusion Body Myositis (IBM)
This is the most common and disabling inflammatory myopathy above the age of 50 1-5,17,18. It starts
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insidiously, over years, at times asymmetrically, and
progresses steadily simulating a late-life muscular dystrophy or slowly progressive motor neuron disease 1-3.
Although IBM is commonly suspected when a patient
with presumed PM did not respond to therapy 1-3, early
involvement of distal muscles, especially foot extensors
and finger flexors, atrophy of the forearms and quadriceps muscles, frequent falls due to quadriceps muscle
weakness causing buckling of the knees, and mild facial muscle weakness, are clues to early clinical diagnosis 1-5,17-21. Axial muscles may be affected resulting in
camptocormia or head drop. Dysphagia occurs in more
than 50% of the patients. 1-5,17-21 IBM is a progressive
disease leading to disability.

Diagnosis and diagnostic work-up
The diagnosis of IM is based on the combination of
clinical history including the pattern of muscle involvement and tempo of disease progression (as described
above), combined with determination of serum muscle
enzymes, muscle biopsy findings and at times auto-antibodies. Ancillary information is provided by electromyography, which can be useful to exclude neurogenic
conditions or assess disease activity. Muscle MRI with
contrast can reveal edema and inflammation in muscle
and fascia and is mainly useful to define and assess the
distribution of atrophic muscles1. The usefulness of muscle MRI has been excessively overestimated because the
findings are not diagnostic for an IM and, contrary to suggestions that it can help selecting the specific muscle to
biopsy, it does not provide more than a careful neurological examination because the surgeon can still obtain tissue from a very atrophic muscle fascicle since the biopsy
is not MRI-or CT-guided and within the seemingly viable
muscle tissue there are long atrophic fascicles (Dalakas
unpublished observations).
Serum muscle enzymes
Creatine Kinase is elevated in all subtypes with active
disease but can be normal when the disease has become
chronic. Very high levels point to NAM, while normal
levels from the outset can be seen in DM and anti-SSOM reflecting predominant pathology in the interstitial
tissues. Aldolase may be also elevated especially if the
fascia is involved 1,24-26.
Muscle biopsy findings
It shows features distinct for each subset and, although not always typical, remains the most reliable diagnostic tool when interpreted in the context of the clinical
findings and processed in the clinician’s expert laboratory

that performs enzyme histochemistry and immunocytochemistry. Findings for each subtype are:
a) in dermatomyositis, there is inflammation predominantly perivascularly, in the interfascicular septae or
at the periphery of the fascicles. The muscle fibers
undergo necrosis and phagocytosis, often in a portion of a muscle fasciculus or the periphery of the
fascicle, due to microinfarcts leading to hypoperfusion and perifascicular atrophy 1-5,25. Perifascicular
atrophy, characterized by layers of atrophic fibers at
the periphery of the fascicles, often with perivascular infiltrates, is diagnostic of dermatomyositis even
without skin manifestations 1-5, 24,25,26;
b) in anti-synthetase syndrome-Overlap Myositis the
histology may overlap with that of DM but this entity
predominantly affects the perimysium with necrotizing features of the perimysial and perifascicular areas
along with actin myonuclear inclusions 1,16,17,25,26;
c) in polymyositis there is inflammation perivascularly
and in multiple foci within the endomysium consisting predominantly of CD8+ T cells invading healthy,
non-necrotic, muscle fibers expressing MHC-I antigen (normal muscle fibers do not express MHC-I
antigen) 1-5.
The MHC/CD8 complex is useful to confirm the
diagnosis and exclude disorders with non-immune
inflammation, as seen in some muscular dystrophies 1-5,17,25;
d) in Inclusion Body Myositis (IBM), in addition to the
same inflammatory pattern described for PM, there
are chronic myopathic changes with increased connective tissue and fiber-size variability; autophagic
vacuoles with bluish-red material “ragged-red” or
cytochrome oxidase–negative fibers due to abnormal
mitochondria; and congophilic amyloid deposits next
to the vacuoles best visualized with crystal violet or
fluorescent optics 1-5,17,18, 20,21. In up to 30% of IBM
patients with the typical clinical IBM- phenotype,
the biopsy does not show vacuoles or amyloid deposits but only inflammation, leading to erroneous
diagnosis of polymyositis 1,17. Such patients have
clinical IBM diagnosed on clinicopathologic correlations 1,17,27;
e) in necrotizing autoimmune myositis there are abundant necrotic fibers invaded or surrounded by
macrophages. Lymphocytic infiltrates are sparse
and MHC-I upregulation mostly in the necrotic fibers1-5,17,25. In a number of patients, the muscle biopsies show deposition of complement on blood vessels
and, as expected, on necrotic fibers. Up to 65% of the
patients have specific, albeit non-pathogenic, antibodies1,12-14,17.
291
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Autoantibodies
Directed against nuclear RNAs or cytoplasmic antigens, autoantibodies are detected in up to 75% of all
IM patients depending on methodology 1. Although their
pathogenic role is unclear, some antibodies appear specific for distinct clinical phenotypes. They include:
a) anti-aminoacyl-tRNA synthetases, detected in 2030% of the patients 1,11,28,29. Among the eight different
anti-synthetases, the antibodies directed against the
histidyl-transfer RNA synthetase (anti-Jo-1), is the
most common accounting for 75% of all anti-synthetases and defines the “anti-synthetase- syndrome”
described above;
b) necrotizing autoimmune myositis-specific antibodies,
against the translational transport protein SRP (Signal Recognition Particle) or against a 100-kd autoantigen identified as HMGCR (3hydroxy3-methylglutaryl-coenzyme A reductase). Because HMGCR
is the pharmacological target of statins 1,11-14, these
antibodies have been thought to be associated with
a prior statin use. These antibodies however are
more often seen in statin-naive patients, and they are
detected in up to 65% of all NAM cases from any
cause 1,13,17. Most importantly, anti-HMGCR may be
more often associated with malignancies rather than
statins. They are disease markers and, contrary to
some publications, they do not have a pathogenic role
as explained below;
c) dermatomyositis-associated antibodies that include:
i) Mi-2, highlighting the typical skin lesions; ii) melanoma differentiation–associated protein-5 (MDA-5)
mostly connected with amyopathic dermatomyositis
or interstitial lung disease 1,30; and iii) transcriptional
intermediary factor-1 (TIF-1) and nuclear matrix protein NXP-2, highly connected with cancer-associated
adult DM 30; and
d) anti-cytosolic 5’-nucleotidase- 1A (cN1A), detected
in 33-51% of IBM patients 31. These antibodies have
no pathogenic significance, and they can be also seen
in patients with other types of myositis or rheumatic
diseases. Their presence in IBM highlights however
the immune dysregulation and B-cell activation.

Triggering factors and
associations
Malignancies
Two IM subtypes are associated with malignancies,
DM and NAM. In DM with malignancy a common antibody is the one against transcriptional intermediary factor-1 (TIF-1), while in NAM antibodies against HMGCR,
especially in patients above the age of 50, are most fre292

quent. Among 349 patients with IM, 75 (21%) had cancer
manifested usually within a year; among those patients,
48% had DM with anti-TIF-1 antibodies and the other
half had NAM with HMGCR 13.
Immune check-point inhibitors (ICPI’s)
An increasing number of patients with advanced malignancies treated with ICPI’s can develop immune-related
neurological complications including inflammatory myopathies 32,33. The neurological events can evolve rapidly,
necessitating the need for vigilance at all stages of treatments, even after completion, because early immunotherapeutic interventions with steroids and IVIg are effective. The main ICPIs currently on the market are directed
against a) CTLA-4: Ipilimumab; b) PD-1: Pembrolizumab
and Nivolumab; and c) PD-L1: Atezollizumab, Avelumab,
and Durvalumab. The process by which ICPI’s trigger autoimmunity has been discussed elsewhere 32. Briefly, tumors, like other antigen presenting cells, express on their
cell surface the inhibitory ligands PD-L1/PDL-2 and B7-1/
B7-2 which are respectively engaged with PD-1 and CTLA-4 on T cells, downregulating T cell responses. These
receptor/ligand interactions essentially act as an off switch,
like “telling the T cells to leave the tumor cells alone” so
T cells do not attack the tumor3 2. The ICPI’s prevent the
CTLA-4 or PD-1 from binding to their respective receptors
CD80/86 and PDL-1 and, by doing so, inhibit the inherent “inhibitory” costimulatory interactions between T cells
and tumor cells, resulting in positive signals. What ICPI’s
essentially do is turning the switch back on resulting in positive costimulation and strong cell activation, like taking
the brakes off the immune system 32. This blockade allows
the T cells to kill tumor cells, but at the same time the resulting enhanced co-stimulation causes an uncontrolled T
cell activation that disrupts immune tolerance resulting in
immune-related events against muscle.
Among all the inflammatory myopathy subtypes, the
most frequent autoimmune myopathies triggered by pembrolizumab, ipilimumab and nivolumab are DM and especially NAM. In some patients, NAM may co-exist with
myasthenia gravis presenting with head drop, proximal
muscle weakness, myalgia, dyspnea, ophthalmoparesis
or bulbar weakness. Among 654 patients receiving ICPI’s (pembrolizumab: 389; nivolumab: 264; both: 1), 5 on
pembrolizumab had biopsy proven myopathies (2 NAM, 1
dermatomyositis, and 2 nonspecific myopathy) 33. Patients
respond to steroids and IVIg especially if treated promptly.
Viruses, including SARS-CoV-2
Among potential triggers, except of the Immune
checkpoint inhibitors discussed above, viruses have
clearly the potential to break tolerance and trigger an im-
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mune inflammatory myopathy. Although IM have been
seen during or after a viral infection, attempts to amplify
viruses from the muscles, including coxsackieviruses, influenza, paramyxoviruses, mumps, cytomegalovirus and
Epstein-Barr virus, have failed 1-5. The best studied viral
connection until now has been with retroviruses. Patients
infected with HIV or human-T-cell-lymphotropic virus-I
develop polymyositis or inclusion-body myositis 1-3, 34-35
with retroviral antigens detected not within the muscle
parenchyma but within some endomysial macrophages
(Trojan-horse mode). The autoinvasive T cells are however clonally driven and some are retroviral-specific 35.
During the present COVID-19 pandemic, there is
evidence that more than 10% of COVID-19-infected
patients develop myopathic symptoms with myalgia,
weakness and elevated CK sometimes at very high CK
levels > 10,000 suggestive of Necrotizing Autoimmune
Myositis (NAM) 36. Although COVID-19-associated myositis has not yet been studied but only characterized as
“skeletal muscle injury” or “rhabdomyolysis”, two just
published cases suggest an autoimmune COVID-19-triggered NAM as summarized 36. One, an 88-year old man
from New York presented with acute bilateral thigh weakness and inability to get up from the toilet, without fever or other systemic symptoms, and very high CK level
(13,581 U/L) 36. He was found COVID-19-positive, given
hydroxychloroquine and a week later his painful weakness improved with CK reduction. The other, a 60-yearold man from Wuhan had a 6-day history of fever, cough
and COVID-19-positive pneumonia with normal strength
and CK; seven days later, although systemically had improved, his CRP doubled and developed painful muscle
weakness with very high CK (11,842 U/L) 36. He was
given IVIg and his strength improved while became
COVID-19-negative.
In a recent retrospective study, patients hospitalized
for a flue also had elevated CK level as high as those seen
in a large series of patients with COVID-19 37 confirming the long-term notion that hyperCKemia can frequently occur in sick patients with an acute viral illness 1-3.
However, an acute onset of severe muscle weakness with
increased inflammatory markers and very high CK levels in the thousands, as noted in the two cases above, is
highly suggestive of an autoimmune inflammatory myopathy within the spectrum of NAM triggered by the
virus, similar to what we first reported with HIV early
in that epidemic 35,36. Considering that very high CK
level and painful muscle weakness were seen in 10% of
COVID-19-positive patients 36, a potentially treatable autoimmune myopathy might have been likely overlooked.
This notion however requires a great deal of caution because without muscle biopsy confirmation and antibody
screening, the diagnosis of COVID-19-NAM remains

still undocumented because myopathic symptoms in a severe systemic viral disease are multifactorial 37. The need
to study COVID-19 muscle invasion is therefore needed
and will be highly interesting because ACE2, the SARSCoV receptor, is reportedly expressed in skeletal muscle
[summarized in 37]. If this is confirmed, COVID-19 may
represent the first virus directly capable of infecting muscle fibers. None of the viruses implicated as possible myositis triggers has been shown to directly infect the muscle fiber and our molecular studies have so far failed to
detect any of them 38; instead, viruses induce an immune
T cell-mediated with clonal expansion of viral-specific T
cells, or macrophage-mediated, muscle fiber autoinvasion
with abundant pro-inflammatory cytokines 1-3, 35,36.
Statin exposure
A very small number of patients early on statin initiation may experience transient myalgia, and some others
transient CK elevation but no muscle weakness. In some
patients, myalgia persists demonstrating statin intolerance. Very rarely, patients may develop rhabdomyolysis
soon after statin initiation. The implication however that
chronic statin administration can, all of a sudden, trigger
“ statin-myopathy” in the form of NAM 11,14 with antibodies against HMGCR, a ubiquitous and non-muscle-specific antigen within the endoplasmic reticulum, has never
been substantiated. Statins can upregulate HMGCR in
cultured cells in vitro, and HMGCR is the target of action
of statins, but studies from many centers throughout the
world have consistently shown that anti-HMGCR autoantibodies are more often seen in statin-naïve NAM patients
and more often connected with cancer 13,39,40. Since NAM
is now the commonest inflammatory myopathy and more
than 25% of Americans above 40 years take statins, the
association between statins and NAM is likely a chance
phenomenon 1,17,41,42. Some authors correctly proposed
that the term “statin myopathy” should not be used 40
because only a minority of NAM patients had statin exposure and, even in those patients, NAM appears many
years after statin initiation making a causative role dubious if not impossible.

Immunopathogenesis
Although the causes of inflammatory myopathies are
unknown, an autoimmune pathogenesis is strongly implicated, and seems to be specific for each subset.
Dermatomyositis
In DM, early activation of complement C5b-9 membranolytic-attack-complex is deposited on the endothelial
cells 1-5,43, leading to capillary necrosis, reduction of endo293
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mysial capillaries, ischemia, and muscle-fiber destruction
resembling microinfarcts 1-5; the remaining capillaries
have dilated lumens to compensate for the ischemia 1-5.
The residual perifascicular atrophy reflects the endofascicular hypoperfusion, which is most prominent at the
periphery of the fascicles. The membrane attack complex
activation is triggered by binding of C1q to endothelial
cells and releases proinflammatory cytokines, upregulates
the adhesion molecules on endothelial cells, and facilitates the migration of activated lymphocytes including
B cells, CD4+T cells and plasmacytoid-dendritic cells to
perimysial and endomysial spaces. Innate immunity also
plays a role based on increased expression of type-I interferon-inducible proteins in the perifascicular regions 44;
this effect appears secondary to ischemic damage which
is probably sensed by the retinoic acid-inducible gene-1
signaling leading to auto-amplification of local inflammation by activating β-interferon and MHC-1 45.
Necrotizing autoimmune myositis and the misconception
of statin association or pathogenicity of antibody
markers
Within the necrotic fibers of NAM, there are macrophages, MHC-I expression and deposition of complement;
these findings have been loosely interpreted to suggest
that in NAM there is complement- mediated cytotoxicity
and the recruitment of macrophages invading the muscle
fibers represent an antibody-dependent cell-mediated cytotoxicity (ADCC) process 11,14,46. There is no convincing
evidence however supporting a pathogenic role of these
antibodies in causing or triggering muscle fiber necrosis
via an ADCC mechanism 41,42. Both, SRP and HMGCR
antibodies, are against ubiquitous and non-muscle-specific antigens firmly localized in the endoplasmic reticulum
and there is no explanation how antibodies against such
cytoplasmic targets can selectively cause muscle fiber
cell necrosis, as discussed 41. Further, MHC-1-expression
and C5b-9 complement deposits are always observed in
necrotic and regenerating fibers from any cause, such as
commonly in muscular dystrophies 47,48, and lack specificity for NAM. Classic work of AG Engel et al dictates
that all necrotic fibers in non-immune myopathies, such
as muscular dystrophies, unambiguously activate complement which in turn stimulates cellular infiltrates and
macrophages 47,48. Further, claims that these antibodies
can cause muscle fiber atrophy or affect regeneration in
vitro49 are irrelevant to the cause of NAM where a macrophage-mediated muscle fiber necrosis causes devastating
muscle destruction, not muscle fiber atrophy. Although
not pathogenic, anti-SRP and anti-HMGCR antibodies
remain important disease markers of diagnostic value because they are detected in up to 65% of NAM patients 1.
294

Polymyositis and Inclusion-Body Myositis
In PM and IBM, CD8+cytotoxic T cells surround and
invade healthy, non-necrotic muscle fibers that aberrantly
express MHC-I 1-3,50-53. MHC-I expression, absent from
the sarcolemma of normal muscle fibers, is probably
induced by cytokines secreted by activated T cells. The
CD8/MHC-I complex is characteristic of polymyositis
and inclusion-body myositis and its detection aids in confirming the histologic diagnosis 2-5,50-53. The CD8+ T cells
contain perforin granules directed towards the surface
of the muscle fibers, resulting in myonecrosis upon release 54,55. Analysis of T-cell receptor molecules expressed
by the infiltrating CD8+ T cells reveals clonal expansion
of T-cell receptor chains and conserved sequences in
the antigen-binding region, suggesting an antigen-driven T-cell response 56-58. This is further supported by the
expression of co-stimulatory molecules and upregulation
of adhesion molecules, chemokines, and cytokines 59-61.
Chemokines and cytokines, including interleukin-6, 8,10,
monocyte chemoattractant protein 1, macrophage inflammatory protein 1a (MIP-1a), or IP-10 and its receptors,
are expressed in the endomysial inflammatory cells and
the neighboring extracellular matrix and may enhance
leukocyte recruitment, trafficking and activation 62. Adhesion of lymphocytes to muscle may be facilitated by
metalloproteinases, which are expressed on the autoinvasive CD8+ T cells and make cell-to-cell contact with
muscle fibers 1,17,63,64. There is also B-cell activation, most
prominent in IBM 65 as supported by the presence of anti-cytoplasmic 5’-nucleotidase 1A (cN1A; NT5C1A) autoantibodies directed against the cN1A nuclear protein
involved in RNA processing 31. These antibodies are not
however pathogenic or IBM-specific but simply denote
the autoimmune dysregulation in IBM muscles. Plasma
cells and myeloid dendritic cells, potent antigen-presenting cells, are also seen among the endomysial infiltrates
of patients with PM, DM, and IBM 66 but their significance is still unknown.
Non-immune factors in Inclusion Body Myositis and
cross-talk between inflammation degeneration and
muscle autophagy
Inclusion-body myositis is a complex disorder because,
in addition to the afore-mentioned autoimmunity, there
co-exists an important degenerative component, highlighted by the presence of congophilic amyloid deposits within
some fibers 18,20,66,67. Similar to Alzheimer’s disease, these
deposits immunoreact against amyloid precursor protein
(APP), β-amyloid, apolipoprotein-E, α-synuclein, presenilin, ubiquitin, and phosphorylated-tau attesting to protein
aggregation 18,20,66. Immunostaining for the ubiquitin or tau
components, TDP43 and p62, has been even advocated as
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Table I. A step-by step approach in the treatment of inflammatory myopathies: 2020 and beyond.
Dermatomyosits (DM) 1-3,72-83
1. High-dose prednisone (oral or intermittent intravenous in acute cases)
2. In steroid-responsive patients add an immunosuppressant [mycophenolate, (most preferable) azathioprine, or
methotrexate]
3. High-dose intravenous immunoglobulin (IVIg) if steps 1-2 fail
4. Rituximab, if IVIg is not sufficiently effective
5. Consider new biologics including eculizumab, other anti-B cell agents or JAK inhibitors
6. Most promising future: anti-complement agents such as eculizumab, ravulizumab (ultomiris), zilucoplan
Polymyositis (PM) 1-3,72-83
1. High-dose prednisone (oral or intermittent intravenous in acute cases)
2. In steroid-responsive patients add an immunosuppressant [mycophenolate, (most preferable) azathioprine, or
methotrexate]
3. High-dose intravenous immunoglobulin (IVIg), if steps 1-2 fail
4. Rituximab, if IVIg is not sufficiently effective
5. If above unsatisfactory, reconsider the diagnosis and explore it with a new muscle biopsy
Necrotizing Autoimmune Myositis (NAM) 1-3,72-83
1. High-dose prednisone (intravenously 1g/daily for 5 days may be needed in acute cases)
2. High-dose intravenous immunoglobulin (IVIg)
3. Rituximab, if IVIg not sufficiently effective
4. Consider new biologics, including eculizumab, other anti-B cell agents or JAK inhibitors
5. Most promising future: anti-complement agents, such as eculizumab, ravulizumab (ultomiris), zilucoplan
Anti-synthetase syndrome-Overlap Myositis (Anti-SS-OM) 1-3,72-83
1. High-dose prednisone (oral or intermittent intravenous in acute cases)
2. In steroid-responsive patients add an immunosuppressant [mycophenolate, (most preferable) azathioprine, or
methotrexate]
3. High-dose intravenous immunoglobulin (IVIg) if steps 1-2 fail
4. Rituximab, if IVIg is not sufficiently effective
5. If interstitial lung disease, may also consider cyclophosphamide
Inclusion Body Myositis 1-3,84-92
1. Physical therapy; CoQ10; encourage participation in a controlled study
2. If dysphagia is prominent, IVIg
3. All trials with immunosuppressants, immunomodulating agents, muscle growth factors TGF-β inhibitors have
failed. Among them, most promising was alemtuzumab in an uncontrolled study

diagnostic markers 1,18,67. It remains however unclear, how
these proteinacious aggregates, which are also seen in other vacuolar myopathies, induce an inflammatory myopathy
and what triggers disease, inflammation or protein aggregation 1,20. Laser microdissection of T-cell-invaded fibers,
compared to non-invaded or vacuolated ones, has revealed
differential upregulation of inflammatory signaling such
as interferon-γ-receptor 68. Compelling evidence suggests
that aging, abnormal proteostasis (the network controlling
proteins) 1,28,20, cell stress induced by MHC-1 or nitric oxide, long-standing inflammation and proinflammatory cytokines like interferon-γ and IL1-β 69-70, may cumulatively
trigger or enhance degeneration leading to further accumulation of stressor molecules and misfolded proteins 1,69-71.

Treatment of DM, PM and NAM
(Tab. I)
Oral prednisone 1 mg/kg, or up to 100 mg per day,

as a single daily dose is the first-line drug based on experience, but not controlled trials 1-6,17,72,73. Some clinicians
prefer adding an immunosuppressant from the outset.
In patients with severe or rapidly worsening disease,
intravenous methylprednisolone 1 gm/kg for 3-5 days
is preferable before starting oral glucocorticoids. After
3-4 weeks, prednisone is tapered as dictated by the patient’s response, preferably by switching the daily dose to
alternate-days 1-3. If by then objective signs of increased
strength and activities in daily living are absent, tapering is accelerated to start the next in-line agent. A tactical error is the practice of “chasing” the CK level as a
sign of response, especially in patients reporting a sense
of “feeling better” but not necessarily stronger. When the
strength improves, the serum CK drops, but fall in CK
alone is not a sign of improvement 1-3.
In glucocorticoid-responsive patients, azathioprine,
mycophenolate mofetil, methotrexate or cyclosporine are
empirically used for “steroid-sparing” 1-3, 17,72,73. When
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interstitial lung disease co-exists, cyclophosphamide or
tacrolimus may be helpful 74. When glucocorticoids fail
to induce remission or in rapidly progressive cases, intravenous immunoglobulin (IVIg) 2 gm/kg is appropriate 1-3;69,70,73. In a double-blind study, IVIg was effective
in refractory dermatomyositis 75; monthly infusions may
be required to maintain remission. In open-label trials,
IVIg also seems effective in polymyositis and necrotizing
autoimmune myositis1-3,17,75. Subcutaneous Ig appears to
sustain remission (Tab. I) 76.
If glucocorticoids and IVIg have not helped, the diagnosis should be revisited, and a repeat muscle biopsy
might be considered. If the diagnosis is re-confirmed,
biologics approved for other immune diseases are further options 1-3,70,73. Among those, the first is rituximab
(anti-CD20 antibody), which at 2 gm (divided in two
bi-weekly infusions) seems effective in several dermatomyositis, polymyositis, and necrotizing autoimmune myositis patients. A placebo-controlled study in 200 patients
however, did not meet the primary end-point largely because of study design; although at week 8 there was no difference between placebo and rituximab, at week 44 when
all patients had received rituximab, 83% met the definition of improvement 77,78. Patients with anti-Jo-1, Mi-2,
or anti-SRP antibodies are also likely to respond 78,79,80.
TNF inhibitors (infliximab, adalimumab, etanercept) are
ineffective and may worsen or trigger disease 1,17. Tocilizumab and IL-1b inhibitors may be of help in small case
series 81,82. Among the new biologics, anti-complement
C5 (eculizumab), should be very promising especially in
dermatomyositis where complement plays a major role
in microangiopathy and muscle fiber necrosis. Eculizumab may be also effective in NAM but controlled studies
have not been done. Overall, the long-term outcome of
treatment for inflammatory myopathies has substantially
improved, with a 10-year survival at > 90% 83. A step-bystep therapeutic approach in all IM subsets is provided in
Table I.

subcutaneous IgG might be an option to diminish exposure. For patients on rituximab, the infusion intervals can
be prolonged to more than 6 months, because both, B-cell
reduction and clinical benefit, can persist longer 36.

Treatment of Inclusion-Body
Myositis
Because of T-cell-mediated cytotoxicity and the enhancement of amyloid aggregates by pro-inflammatory
cytokines as outlined earlier, immunosuppressive agents
have been tried in IBM but all failed probably because
the disease starts long before patients seek medical advice, when the degenerative cascade is already advanced
and inflammatory mediators have enhanced degeneration
and autophagy 1-3,17,84-86. Glucocorticoids, methotrexate,
cyclosporine, azathioprine or mycophenolate are ineffective and, although some patients initially experience
mild improvements, there is no long-term benefit 1,17,84.
IVIg is ineffective in controlled trials but may transiently
help some patients, especially those with life-threatening
dysphagia where is the treatment of choice based on statistically significant changes in the controlled trial 87,88.
Alemtuzumab may provide short-term stabilization 89 but
a controlled study is needed. Anti- IL1-receptor (Anakinra) 90 and IL1 receptor antagonist (Ilaris) also failed 91.
Trials targeting muscle-inhibiting TGF-β molecules or
muscle growth factors are also disappointing and doubleblind studies have been clearly negative92. Although
life expectancy seems normal, most patients with endstage disease require assistive devices such as cane, walker, or wheelchair 22. Dysphagia can be life threatening if
IVIg has not helped.

Immunotherapies for IM during COVID-19

Evolution of the IM field in the
context of the Mediterranean
Society of Myology (MSM) with a
personal tribute to G. Nigro

Patients with IM have been justifiably concerned as
to whether their disease status adds an additional risk
placing them into an “immunosuppressed or immunocompromised” category. As discussed previously 36, there
is no evidence that the inflammatory myopathy itself
makes them more susceptible to COVID-19 or the immunosuppressive therapies they are receiving have such a
potential. If clinically stable and not lymphopenic, there
is no data-driven reasons to change anything and disturb
clinical stability. For patients on monthly IVIg, there may
be even a theoretical advantage that IVIg offers additional
protection due to natural autoantibodies 36; if IVIg is not
infused as home-infusion, switching to self-administered

Inflammatory myopathies have been discovered and
subsequently studied by Neurology scholars with expertise in neuromuscular pathology fostering progress in
muscle immunopathology, disease recognition, subset
subtyping and pathogenesis. Over the last 30 years the
very best minds and Neurology scholars in this field with
leaders like W King Engel, Valerie Askanas, Andrew Engel, George Karpati, Victor Dubovitz and many others
from USA, Italy, France, Australia, Israel etc. have participated on a regular basis in the MSM meetings. I have
had the chance to be there every year almost since the
creation of the MSM and have hosted two such events in
Greece, one in Corfu and another one in Athens. Writing
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this piece in the memory of Giovani Nigro brings back a
blend of unique pleasantries of good science and humour
in a relaxing and friendly atmosphere of picturesque environments and scholarly, formal, and informal, discussions about inflammatory myopathies. Being honoured
by Giovanni in his unique style at the gala dinner among
the best of friends and neuromuscular colleagues was the
epitomy of the MSM that I will never forget.
This opportunity in honouring the memory of
Giovanni Nigro and the unique meetings he has organized
and overseen, is also an introspective on the future of the
IM field as it is now moving from the neuromuscular clinicians/scientists that splendidly served it for years and
advanced the field, to other subspecialties with different
training backgrounds. We have all witnessed the last few
years that neurologists with muscle pathology and immunopathology training are becoming increasingly scarce as
very few of us continue to keep an active muscle pathology
laboratory. Muscle biopsies are mostly performed now by
surgeons, read by general pathologists either on paraffin
sections with just the very basic – if any – immunopathology or enzyme histochemistry stains on fresh-frozen sections, and without knowledge of the clinical neuromuscular evaluation. The lack of clinicopathologic correlation,
a fundamental principle of a neuromuscular neurologist
for the diagnosis of myopathies, as pioneered by WK Engel and taught all of us, may be impacting on the identification of the correct inflammatory myopathy subtype and
the distinction from dystrophies. We had been proud of
our unique expertise to precisely assess and quantify the
patient’s muscle strength, being aware on how best to distinguish the contribution of functional weakness or pains
from true muscle weakness, and bring this to diagnostic
fruition by personally performing muscle biopsy, selecting the muscle to biopsy, looking at the slides and, after
combining clinical with histology, initiate proper therapy. Concurrently, research on expanding the diagnostic
muscle histopathology, immunopathology or molecular
muscle pathology had flourished. Today, most clinicians
involved in the diagnosis and care of patients with IM are
of different subspecialties with different training backgrounds, such as rheumatologists, rheumatoneurologists
or neurologists/elctromyographers. The prior focus on
myopathology and molecular muscle immunopathology
is slowly being shifted to serology, circulating humoral
factors and antibodies, and muscle imaging. Whether will
prove more fruitful remains to be seen.
Serving for more than 40 years as head of Neuromuscular service with still a fully functioning laboratory
and having trained more than a hundred neuromuscular
fellows around the world, I am also witnessing the directional shift of our neuromuscular trainees who are mostly
centered around electromyography. We are not however

to blame; it is economics that has prevented the maintenance of active neuromuscular pathology laboratories
in many Universities. As a result, previously flourishing
regional myology meetings, such as the MSM under Dr
Giovanni Nigro’s leadership, have vanished as if there is
not need to have them; electromyographers go to electrophysiology meetings, rheumatologists to rheumatology
meetings and general neurologists to neurology meetings.
Writing this in honouring of Giovanni Nigro’ memory, I remain with the pleasant memories of blending the
many years of myology progress with innovative discussions about culture and civilization with stimulating
leaders in the clinical and basic science of muscle diseases. These unforgettable memories in the middle of the
COVID-19 pandemic bring me back to the sad reality
that the wonderful Giovanni Nigro’s era of the MSM may
never return; yet at the same time, as the sun comes after
a storm, these memories also bring shining hopes on how
Giovanni’s legacy will build a bright future for our field.
After the COVID-19 pandemic ends, we should be all
armed with enthusiasm, determination and organizational to re-build the society from where it started, teach the
new generation of neuromuscular experts what we have
all learnt, and provide them with the stimulus on how best
to combine the excellence in the clinic with histopathology, immunology, immungenetics and molecular biology to advance the filed towards effective target-specific
therapies. Afterall, the advances in molecular science and
means of communication are on our side. This will be
Giovani’s best legacy.
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